World Wires · story 5387 · unverified · 1 source(s)

Nasus Pharma Doses First Patient in Phase 1 Study of NS003

Nasus Pharma initiated dosing in a Phase 1 study for its intranasal ondansetron formulation, with topline data expected in Q4 2026.

Open in the desk

Coverage

• Nasus Pharma Doses First Patient in Phase 1 Study of NS003 GlobeNewswire: public companies · tier D · clear net · 2026-09-29 12:00 UTC

What this site indexes